At what ages and minimum body weight is Paxlovid (nirmatrelvir + ritonavir) approved for treatment of COVID‑19?

Paxlovid Age and Weight Approval Criteria

Paxlovid (nirmatrelvir/ritonavir) is approved for patients aged ≥12 years who weigh at least 40 kg for the treatment of mild to moderate COVID-19. 1, 2, 3, 4

Age-Specific Approval

• Minimum age: 12 years old 1, 2, 3, 4
• The emergency use authorization and subsequent approvals specify this age cutoff across multiple regulatory jurisdictions 3, 4
• Children under 12 years are not approved for Paxlovid treatment due to lack of trial data in this population 5

Weight Requirements

• Minimum body weight: 40 kg (approximately 88 pounds) 1, 2, 3, 4
• This weight threshold applies to all patients aged 12 years and older 2, 3
• Patients weighing less than 40 kg should not receive Paxlovid, as safety and efficacy data are not available for this population 5

Dosing Regimen for Approved Patients

• Standard dose: Nirmatrelvir 300 mg (two 150 mg tablets) plus ritonavir 100 mg (one tablet) taken orally every 12 hours for 5 days 1, 2, 3
• Treatment must be initiated within 5 days of symptom onset 1, 3, 4

Special Population Considerations

Renal Impairment

• Moderate renal impairment (eGFR 30-59 mL/min): Reduce nirmatrelvir dose to 150 mg while maintaining ritonavir 100 mg, given twice daily for 5 days 1, 2
• Severe renal impairment (eGFR <30 mL/min): Paxlovid is not recommended 2

Hepatic Impairment

• Severe hepatic impairment (Child-Pugh Class C): Paxlovid is not recommended due to lack of safety data 1

Pregnancy

• Paxlovid may be offered to pregnant individuals to reduce disease progression, with no serious adverse reactions reported to date in WHO Vigibase 1, 5

Critical Safety Consideration

• Drug-drug interactions are the primary safety concern due to ritonavir's potent CYP3A4 inhibition 1, 5, 6, 7
• Use the Liverpool COVID-19 Drug Interaction Tool to systematically check all concomitant medications before prescribing 1, 5, 7